Windward Bio shares close 68% above $17 IPO price on Nasdaq debut

SHANGHAI -- November 16, 2026 -- Windward Bio, a clinical-stage biotechnology company founded in 2024, closed its first Nasdaq trading day on November 13, 2026 at $28.50 per share, 68% above its $17.00 IPO price. The $11.50 gain per share lifted the company's market capitalization to about $1.69 billion, against roughly $1.01 billion at the offer price by our calculation.

The $1.69 billion figure works out to about 59 million shares ($1.69 billion divided by $28.50), assuming the release values the company at the closing price. The company trades as WWB. It did not disclose the gross proceeds of the offering.

Qiming Venture Partners backed Windward Bio from Series A through the IPO

Qiming Venture Partners invested in Windward Bio's Series A in 2025 and its Series B in 2026, and it took part in the IPO round. The listing is Qiming's 11th IPO in 2026. Windward Bio reached the public market about two years after its 2024 founding.

Qiming Principal Alexander Sinclair Wilson said the firm believes long-acting biologics will reshape treatment of severe chronic respiratory and skin diseases. He said he expects Windward Bio to deliver on that potential.

Windward Bio's lead antibody WIN378 is in a Phase 2/3 asthma study

WIN378 is an anti-TSLP monoclonal antibody. The company describes it as potentially novel and engineered for improved potency and extended half-life. It is being tested in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and in SIRIUS, a Phase 2 study in chronic obstructive pulmonary disease (COPD).

The second named program, WIN027, is a clinical-stage, long-acting bispecific antibody targeting TSLP and IL-13. The company lists asthma, COPD and atopic dermatitis as its target diseases.

Windward Bio licenses both named programs from outside developers

Windward Bio holds exclusive global rights to WIN378 through a licensing agreement with Kelun-Biotech and Harbour BioMed. The license excludes Greater China and certain Asian countries. The company licensed WIN027 separately from Qyuns Therapeutics. Both programs named in the release are therefore in-licensed, and the roughly $1.69 billion valuation rests on them.

Qiming says it manages eleven US dollar funds and seven RMB funds with $9.5 billion in capital raised. It reports backing more than 630 companies, of which more than 290 have exited through IPOs, M&A or other routes. On those rounded figures, that is about 46%.

Published by:
fairsonline_team
Products
News Type